UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 小児や青年の2型糖尿病の疫学、症状、および診断epidemiology presentation and diagnosis of type 2 diabetes mellitus in children and adolescents [show details]
… glucose tolerance (IGT) – Plasma glucose ≥140 mg/dL to 199 mg/dL (≥7.8 mmol/L to 11.0 mmol/L) measured two hours after a glucose load of 1.75 g/kg (maximum dose of 75 g) in an oral glucose tolerance test …
2. ループ利尿剤：最大有効量および主な副作用loop diuretics maximum effective dose and major side effects [show details]
… given at equipotent doses. Going above these maximum doses will produce little or no further diuresis but may increase the risk of side effects. The maximum effective diuretic dose differs in patients …
3. 家族性地中海熱のマネージメントmanagement of familial mediterranean fever [show details]
…generally start with a lower dose and increase the dose by 0.5 to 0.6 mg according to the patient response and tolerance without exceeding the maximum recommended daily dose of colchicine, which is 2 mg …
4. 小児や青年の1型糖尿病の疫学、症状、および診断epidemiology presentation and diagnosis of type 1 diabetes mellitus in children and adolescents [show details]
…≥200 mg/dL (11.1 mmol/L) measured two hours after a glucose load of 1.75 g/kg (maximum dose of 75 g) in an oral glucose tolerance test (OGTT). Most children and adolescents are symptomatic and have plasma …
5. 小児や青年の不眠症への薬物療法：エビデンスに基づいた治療法pharmacotherapy for insomnia in children and adolescents a rational approach [show details]
… tolerance to antihistamines tends to develop, necessitating increasing doses,… 0.5 mg each week as needed to a maximum 3 mg for children or 5 mg for adolescents, as suggested in a consensus guideline . These relatively small doses and advance administration…

English Journal

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.

Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P.
Diabetologia. 2019 Jun;62(6)948-958.
The study aimed to examine the efficacy of 12 weeks of monthly evolocumab or placebo in lowering LDL-cholesterol (LDL-C) in individuals with type 2 diabetes and hypercholesterolaemia or mixed dyslipidaemia and on a maximum-tolerated statin of at least moderate intensity. For this randomised, placeb
PMID 30953107

A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of Re-liposome in patients with metastatic tumors.

Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, Teng HW, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL.
EJNMMI research. 2019 May;9(1)46.
Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, Re-liposome that has been developed by the Institute of Nuclear Energy Research (INER) d
PMID 31119414

Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation.

Arya VB, Kalitsi J, Hickey A, Flanagan SE, Kapoor RR.
Endocrinology, diabetes & metabolism case reports. 2019 May;2019().
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approximately 50% of patients with HH are diazoxide resistant. However, marked diazoxide sensitivity resulting in severe hyperglycaemia is extremely uncommon and not reported previously in the context of HH
PMID 31096182

Japanese Journal

Long-term Impact of Cardiorespiratory Fitness on Type 2 Diabetes Incidence: A Cohort Study of Japanese Men

Kawakami Ryoko,Higuchi Mitsuru,Miyachi Motohiko,Blair Steven N.,Sawada Susumu S.,Lee I-Min,Gando Yuko,Momma Haruki,Terada Shin,Kinugawa Chihiro,Okamoto Takashi,Tsukamoto Koji
Ｊｏｕｒｎａｌ　ｏｆ　Ｅｐｉｄｅｍｉｏｌｏｇｙ 28(5), 266-273, 2018
… We sought to examine the association between cardiorespiratory fitness (CRF) and incidence of type 2 diabetes considering the follow-up period in a cohort of Japanese men with a maximum follow-up period of 23 years.Methods: … During 1986–2009, participants were followed for development of type 2 diabetes, which was diagnosed using fasting blood tests, self-administered questionnaires, or oral glucose tolerance tests after urinary tests from annual health checkups. …
NAID 130006732099

妊娠に伴い血糖コントロールが悪化したミトコンドリア糖尿病の姉妹例

宮田佳穂里,玉置真也,吉松卓,山本昇平,山本怜佳,河島明,若﨑久生
糖尿病 61(4), 181-188, 2018
ミトコンドリア糖尿病は本邦の糖尿病患者の約1 ％を占めるが，妊娠がミトコンドリア糖尿病に及ぼす影響はまだよく知られていない．今回我々はミトコンドリア遺伝子A3243G変異を呈したミトコンドリア糖尿病の妊娠経過を姉妹例で観察できた．症例1は25歳女性，妊娠28週時に妊娠糖尿病と診断され，妊娠34週に切迫早産にてリトドリンを投与されてからインスリンが必要となり最大36単位/日を必要と …
NAID 130006729019

2型糖尿病患者における半減期の異なる2種類のdipeptidyl peptidase 4阻害薬テネリグリプチンとシタグリプチンの血糖変動およびGLP-1に対する効果の比較検討

黒住旭,岡田洋右,須貝彗,鳥本桂一,田中良哉
産業医大誌 40(1), 1-9, 2018
今回我々は，日本人2型糖尿病患者において，半減期の異なるdipeptidyl peptidase 4 (DPP4) 阻害薬であるテネリグリプチンとシタグリプチンによる血糖変動とglucagon like peptide-1 (GLP-1) 分泌に対する効果に関して検討した．14名の薬剤未使用2型糖尿病患者をテネリグリプチン20 mg先行群 (7名) もしくはシタグリプチン50 m …
NAID 130006515858